Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 3, 2020--
The “Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024” report has been added to ResearchAndMarkets.com’s offering.
The US meningococcal vaccines market is expected to grow over the forecast period due to incremental increases in MenACWY and MenB coverage rates in adolescents and young adults before the anticipated introduction of GlaxoSmithKline’s and Pfizer’s pentavalent vaccines in H2 2023/H1 2024.
Beyond this period, market growth will be driven by the uptake of pentavalent vaccines, which could significantly boost coverage for the MenB component by linking the higher coverage rates observed with the booster dose of MenACWY in adolescents (53.7% in 2019) to the suboptimal coverage rates with MenB vaccines (21.8% of 17-year-olds received at least one MenB dose in 2019). The pentavalent vaccines would also be more convenient for physicians and patients as they would reduce the total number of doses required during adolescence from four (two MenACWY + two MenB) to three.
The overall likelihood of approval of a Phase I antibacterial, mycobacterial, or fungal asset is 24.6%, and the average probability an asset advances from Phase III is 62.9%. Antibacterial, mycobacterial, or fungal assets take 9.6 years on average from Phase I to approval, slightly longer than the 9.1 years in the overall infectious disease space.
Key Topics Covered:
- Latest key takeaways
- Diagnostics and screening
- Risk factors
- Vaccination guidelines in major markets
KEY REGULATORY EVENTS
- Sanofi Pasteur Head Loew On The Vaccine Unit’s Future Growth Drivers
PROBABILITY OF SUCCESS
CLINICAL TRIAL LANDSCAPE
- Sponsors by status
- Sponsors by phase
- Meningococcal ACWY vaccines
- Meningococcal B vaccines
- Pipeline pentavalent vaccines
KEY UPCOMING EVENTS
KEY OPINION LEADER INSIGHTS
- MenACWY vaccines
- Pentavalent vaccines
- MenB vaccines
- Improvements in meningococcal vaccination coverage rates in at-risk populations
- Vaccines with more durable humoral responses
- Improvements in MenB vaccination coverage rates in US adolescents and young adults
- Prescription information
For more information about this report visit https://www.researchandmarkets.com/r/qblgem
View source version on businesswire.com:https://www.businesswire.com/news/home/20201103005304/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 11/03/2020 06:15 AM/DISC: 11/03/2020 06:15 AM